Page last updated: 2024-11-11

epolactaene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

epolactaene: a neuritogenic compound in human neuroblastoma cells; isolated from Penicillium sp. BM1689-P; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6442272
CHEMBL ID183869
MeSH IDM0251105

Synonyms (13)

Synonym
epolactaene
CHEMBL183869
167782-17-4
4s7a4hla92 ,
unii-4s7a4hla92
Q15410943
methyl (2e,3e,5e,9e)-2-ethylidene-11-[(1r,5r)-4-hydroxy-4-methyl-2-oxo-6-oxa-3-azabicyclo[3.1.0]hexan-1-yl]-4,10-dimethyl-11-oxoundeca-3,5,9-trienoate
epolactaene, (+)-
(+)-epolactaene
methyl (2e,3e,5e,9e)-2-ethylidene-11-((1r,5r)-4-hydroxy-4-methyl-2-oxo-6-oxa-3-azabicyclo(3.1.0)hex-1-yl)-4,10-dimethyl-11-oxo-3,5,9-undecatrienoate
3,5,9-undecatrienoic acid, 2-ethylidene-11-[(1r,5r)-4-hydroxy-4-methyl-2-oxo-6-oxa-3-azabicyclo[3.1.0]hex-1-yl]-4,10-dimethyl-11-oxo-, methyl ester, (2e,3e,5e,9e)-
DTXSID301045462
methyl (2e,3e,5e,9e)-2-ethylidene-11-((1r,5r)-4-hydroxy-4-methyl-2-oxo-6-oxa-3-azabicyclo[3.1.0]hexan-1-yl)-4,10-dimethyl-11-oxoundeca-3,5,9-trienoate

Research Excerpts

Overview

Epolactaene is a microbial metabolite isolated from the fungal strain Penicillium sp.

ExcerptReferenceRelevance
"Epolactaene is a microbial metabolite isolated from the fungal strain Penicillium sp. "( Structure-activity relationships of epolactaene derivatives: structural requirements for inhibition of Hsp60 chaperone activity.
Hayashi, Y; Kakeya, H; Nagumo, Y; Osada, H; Shoji, M; Uno, T; Yamaguchi, J, 2004
)
2.04
"Epolactaene is a microbial metabolite isolated from Penicillium sp., from which we synthesized its derivative ETB (epolactaene tertiary butyl ester). "( Epolactaene binds human Hsp60 Cys442 resulting in the inhibition of chaperone activity.
Dohmae, N; Hayashi, Y; Kakeya, H; Nagumo, Y; Osada, H; Shoji, M, 2005
)
3.21
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID382217cytotoxicity against human BALL1 cells by MTT assay2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Syntheses and applications of fluorescent and biotinylated epolactaene derivatives: Epolactaene and its derivative induce disulfide formation.
AID244420Competitive binding to human heat shock protein Hsp60; 60-90%2004Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
Structure-activity relationships of epolactaene derivatives: structural requirements for inhibition of Hsp60 chaperone activity.
AID248710inhibitory concentration against human neuroblastoma SH-SY5Y cells (cell viability was assessed by MTT assay)2004Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
Structure-activity relationships of epolactaene derivatives: structural requirements for inhibition of Hsp60 chaperone activity.
AID252840In vitro Hsp60 chaperone activity in mitochondrial malate dehydrogenase (MDH) refolding assay2004Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
Structure-activity relationships of epolactaene derivatives: structural requirements for inhibition of Hsp60 chaperone activity.
AID248667inhibitory concentration against human T-lymphoma Jurkat cells (cell viability was assessed by MTT assay)2004Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
Structure-activity relationships of epolactaene derivatives: structural requirements for inhibition of Hsp60 chaperone activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (13.33)18.2507
2000's11 (73.33)29.6817
2010's1 (6.67)24.3611
2020's1 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.33 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]